Ovid is considering expanding Phase III trial size of gaboxadol in Angelman syndrome
This potential trial size expansion could make meeting the mid-2020 readout target more challenging. Credit: Vitalii Vodolazskyi / Shutterstock.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more